Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INTS Stock Forecast 2026-2027
$5.30
Current Price
$13.46M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to INTS Price Targets
+2,258.5%
To High Target of $125.00
+466.0%
To Median Target of $30.00
+126.4%
To Low Target of $12.00
INTS Price Momentum
-2.9%
1 Week Change
-11.4%
1 Month Change
-88.5%
1 Year Change
-48.3%
Year-to-Date Change
-89.1%
From 52W High of $48.55
+14.6%
From 52W Low of $4.63
📊 TOP ANALYST CALLS
Did INTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Intensity Therapeutics is one of their latest high-conviction picks.
Latest INTS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, INTS has a bullish consensus with a median price target of $30.00 (ranging from $12.00 to $125.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $5.30, the median forecast implies a 466.0% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Robert Wasserman at Benchmark, suggesting a 126.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INTS Analyst Ratings
6
Buy
0
Hold
0
Sell
INTS Price Target Range
Low
$12.00
Average
$30.00
High
$125.00
Current: $5.30
Latest INTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 20, 2025 | Benchmark | Robert Wasserman | Speculative Buy | Maintains | $1.50 |
| Aug 12, 2025 | Brookline Capital | Kumaraguru Raja | Buy | Upgrade | $3.00 |
| Jan 13, 2025 | Alliance Global Partners | James Molloy | Buy | Initiates | $8.50 |
| Nov 21, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $5.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Initiates | $5.00 |
| Jul 11, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| May 16, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Mar 21, 2024 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Nov 14, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Aug 24, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Reiterates | $12.00 |
| Jul 18, 2023 | Benchmark | Robert Wasserman | Speculative Buy | Initiates | $12.00 |
Intensity Therapeutics Inc. (INTS) Competitors
The following stocks are similar to Intensity Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
INTS
Intensity Therapeutics
mkt cap
13.46M
Intensity Therapeutics Inc. (INTS) Financial Data
Intensity Therapeutics Inc. has a market capitalization of $13.46M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -156.9%.
Valuation Metrics
Market Cap
$13.46M
Enterprise Value
$1.65M
P/E Ratio
-0.6x
PEG Ratio
-1.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+88.5%
Current Ratio
5.9x
Debt/Equity
0.9x
ROE
-156.9%
ROA
-79.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Intensity Therapeutics Inc. (INTS) Business Model
About Intensity Therapeutics Inc.
What They Do
Develops innovative cancer treatments through immunotherapy.
Business Model
The company focuses on creating proprietary immune-based drug products that enhance traditional chemotherapy. By utilizing its DfuseRxSM technology, Intensity Therapeutics integrates chemotherapy with immunotherapy, generating a localized treatment that triggers a systemic immune response, thereby aiming to improve patient survival rates and reduce side effects.
Additional Information
Intensity Therapeutics is actively involved in clinical trials, targeting various types of solid tumors, including breast, colorectal, and liver cancers. The company’s commitment to advancing medical research positions it as a significant player in the biotech industry, contributing to both scientific innovation and improved patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Mr. Lewis H. Bender M.A., M.B.A., M.S.
Country
United States
IPO Year
2022
Website
www.intensitytherapeutics.comIntensity Therapeutics Inc. (INTS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apr 16, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
4 days ago
Quick Summary
Intensity Therapeutics, Inc. (Nasdaq: INTS) has won the 2026 Pinnacle Award for Innovator in Biotech Solutions for its intratumoral injection platform and lead drug candidate INT230-6.
Why It Matters
The Platinum Award recognition enhances Intensity Therapeutics' credibility, potentially attracting investment and increasing stock value as it highlights innovation in a competitive biotech space.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy) due to increasing optimism about its earnings prospects.
Why It Matters
The upgrade to Zacks Rank #2 signals increased confidence in Intensity Therapeutics' earnings potential, likely boosting investor interest and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
23 days ago
Quick Summary
Intensity Therapeutics raised over $20 million in 2025 and has $11.9 million in cash as of year-end. A study published in eBioMedicine showed favorable results for INT230-6 in cancer patients.
Why It Matters
Intensity Therapeutics raised $20 million and reported promising clinical data for its cancer treatment, enhancing its financial stability and potential for future growth, appealing to investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Intensity Therapeutics, Inc. has been granted US Patent 12,496,345 and now holds patents in 41 countries for its intratumoral cancer treatment technology, enhancing its intellectual property portfolio.
Why It Matters
The new patent enhances Intensity Therapeutics' competitive edge and market position, potentially leading to increased revenue and investor confidence as it protects innovative cancer therapies.
Source: PRNewsWire
Market Sentiment:
Neutral
Intensity Therapeutics Updates Breast Cancer Trial, Files To Resume Enrollment Following Study Pause
1 month ago
Quick Summary
Intensity Therapeutics Inc. (NASDAQ: INTS) has updated investors on the INVINCIBLE-4 Study, indicating ongoing developments in their clinical research.
Why It Matters
The update on the INVINCIBLE-4 Study could impact Intensity Therapeutics' stock performance and future prospects, influencing investor sentiment and potential market valuation.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
In the INVINCIBLE-4 Study, 71.4% of patients receiving INT230-6 prior to standard care achieved a pathological complete response, compared to 33% in the standard care group. Cohort A had 44% fewer severe adverse events.
Why It Matters
The INVINCIBLE-4 Study results suggest INT230-6 significantly improves treatment outcomes and reduces severe side effects, potentially enhancing the company's market position and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About INTS Stock
What is Intensity Therapeutics Inc.'s (INTS) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Intensity Therapeutics Inc. (INTS) has a median price target of $30.00. The highest price target is $125.00 and the lowest is $12.00.
Is INTS stock a good investment in 2026?
According to current analyst ratings, INTS has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INTS stock?
Wall Street analysts predict INTS stock could reach $30.00 in the next 12 months. This represents a 466.0% increase from the current price of $5.30. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Intensity Therapeutics Inc.'s business model?
The company focuses on creating proprietary immune-based drug products that enhance traditional chemotherapy. By utilizing its DfuseRxSM technology, Intensity Therapeutics integrates chemotherapy with immunotherapy, generating a localized treatment that triggers a systemic immune response, thereby aiming to improve patient survival rates and reduce side effects.
What is the highest forecasted price for INTS Intensity Therapeutics Inc.?
The highest price target for INTS is $125.00 from at , which represents a 2,258.5% increase from the current price of $5.30.
What is the lowest forecasted price for INTS Intensity Therapeutics Inc.?
The lowest price target for INTS is $12.00 from Robert Wasserman at Benchmark, which represents a 126.4% increase from the current price of $5.30.
What is the overall INTS consensus from analysts for Intensity Therapeutics Inc.?
The overall analyst consensus for INTS is bullish. Out of 4 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are INTS stock price projections?
Stock price projections, including those for Intensity Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:08 AM UTC